|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Traverso LW: Pancreatic cancer: surgery
alone is not sufficient. Surg Endosc. 20(Suppl 2): S446–S449. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frigeri M, De Dosso S, Castillo-Fernandez
O, Feuerlein K, Neuenschwander H and Saletti P: Chemotherapy in
patients with advanced pancreatic cancer: too close to death?
Support Care Cancer. 21:157–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vladov N, Takorov I, Kazarov K, et al:
Surgical potentialities for the treatment of pancreatic cancer.
Hepatogastroenterology. 59:280–283. 2012.PubMed/NCBI
|
|
5
|
Sultana A, Cox T, Ghaneh P and Neoptolemos
JP: Adjuvant therapy for pancreatic cancer. Recent Results Cancer
Res. 196:65–88. 2012. View Article : Google Scholar
|
|
6
|
Cavadas MA, Nguyen LK and Cheong A:
Hypoxia-inducible factor (HIF) network: insights from mathematical
models. Cell Commun Signal. 11:422013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Evans CE, Branco-Price C and Johnson RS:
HIF-mediated endothelial response during cancer progression. Int J
Hematol. 95:471–477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shibaji T, Nagao M, Ikeda N, et al:
Prognostic significance of HIF-1 alpha overexpression in human
pancreatic cancer. Anticancer Res. 23:4721–4727. 2003.PubMed/NCBI
|
|
9
|
Cheng ZX, Sun B, Wang SJ, et al: Nuclear
factor-κB-dependent epithelial to mesenchymal transition induced by
HIF-1α activation in pancreatic cancer cells under hypoxic
conditions. PLoS One. 6:e237522011.
|
|
10
|
Malemud CJ: Matrix metalloproteinases
(MMPs) in health and disease: an overview. Front Biosci.
11:1696–1701. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sato H and Takino T: Coordinate action of
membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2
enhances pericellular proteolysis and invasion. Cancer Sci.
101:843–847. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou C and Petroll WM: MMP regulation of
corneal keratocyte motility and mechanics in 3-D collagen matrices.
Exp Eye Res. 121:147–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Zucker S, Pulkoski-Gross A, et al:
Conversion of stationary to invasive tumor initiating cells (TICs):
role of hypoxia in membrane type 1-matrix metalloproteinase
(MT1-MMP) trafficking. PLoS One. 7:e384032012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shaverdashvili K, Wong P, Ma J, Zhang K,
Osman I and Bedogni B: MT1-MMP modulates melanoma cell
dissemination and metastasis through activation of MMP2 and RAC1.
Pigment Cell Melanoma Res. 27:287–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanaka M, Sato H, Takino T, Iwata K, Inoue
M and Seiki M: Isolation of a mouse MT2-MMP gene from a lung cDNA
library and identification of its product. FEBS Lett. 402:219–222.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fillmore HL, VanMeter TE and Broaddus WC:
Membrane-type matrix metalloproteinases (MT-MMPs): expression and
function during glioma invasion. J Neurooncol. 53:187–202. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Davidson B, Goldberg I, Berner A, et al:
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases
messenger RNA in ovarian carcinoma cells in serous effusions. Am J
Clin Pathol. 115:517–524. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Docampo MJ, Cabrera J, Rabanal RM and
Bassols A: Expression of matrix metalloproteinase-2 and -9 and
membrane-type 1 matrix metalloproteinase in melanocytic tumors of
dogs and canine melanoma cell lines. Am J Vet Res. 72:1087–1096.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen L, Di D, Luo G, et al: Immunochemical
staining of MT2-MMP correlates positively to angiogenesis of human
esophageal cancer. Anticancer Res. 30:4363–4368. 2010.PubMed/NCBI
|
|
20
|
Ito E, Yana I, Fujita C, et al: The role
of MT2-MMP in cancer progression. Biochem Biophys Res Commun.
393:222–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abraham R, Schafer J, Rothe M, Bange J,
Knyazev P and Ullrich A: Identification of MMP-15 as an
anti-apoptotic factor in cancer cells. J Biol Chem.
280:34123–34132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu S, Zhou Y, Wang L, et al:
Transcriptional upregulation of MT2-MMP in response to hypoxia is
promoted by HIF-1α in cancer cells. Mol Carcinog. 50:770–780.
2011.PubMed/NCBI
|
|
23
|
Sobin LH and Fleming ID: TNM
Classification of Malignant Tumors, fifth edition (1997). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Elias JM, Margiotta M and Gaborc D:
Sensitivity and detection efficiency of the peroxidase
antiperoxidase (PAP), avidin-biotin peroxidase complex (ABC), and
peroxidase-labeled avidin-biotin (LAB) methods. Am J Clin Pathol.
92:62–67. 1989.
|
|
25
|
Ikeda N, Nakajima Y, Tokuhara T, et al:
Clinical significance of aminopeptidase N/CD13 expression in human
pancreatic carcinoma. Clin Cancer Res. 9:1503–1508. 2003.PubMed/NCBI
|
|
26
|
Hu Y, Liu J and Huang H: Recent agents
targeting HIF-1α for cancer therapy. J Cell Biochem. 114:498–509.
2013.
|
|
27
|
Chen C and Yu Z: siRNA targeting
HIF-1alpha induces apoptosis of pancreatic cancer cells through
NF-kappaB-independent and -dependent pathways under hypoxic
conditions. Anticancer Res. 29:1367–1372. 2009.
|
|
28
|
Plaisier M, Koolwijk P, Hanemaaijer R, et
al: Membrane-type matrix metalloproteinases and vascularization in
human endometrium during the menstrual cycle. Mol Hum Reprod.
12:11–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Quick RE, Dunlap JA and Jessen JR:
Expression analysis of zebrafish membrane type-2 matrix
metalloproteinases during embryonic development. Gene Expr
Patterns. 12:254–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamahatsu K, Matsuda Y, Ishiwata T, Uchida
E and Naito Z: Nestin as a novel therapeutic target for pancreatic
cancer via tumor angiogenesis. Int J Oncol. 40:1345–1357.
2012.PubMed/NCBI
|
|
31
|
Nanashima A, Shibata K, Nakayama T, et al:
Relationship between microvessel count and clinicopathological
characteristics and postoperative survival in patients with
pancreatic carcinoma. Hepatogastroenterology. 59:1964–1969.
2012.
|
|
32
|
Iki K, Tsutsumi M, Kido A, et al:
Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1
MMP and tissue inhibitor of metalloproteinase 2 and activation of
proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated
with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis. 20:1323–1329.
1999. View Article : Google Scholar : PubMed/NCBI
|
